Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1958 1
1963 2
1964 2
1980 1
1981 6
1982 11
1983 18
1984 16
1985 23
1986 28
1987 62
1988 53
1989 58
1990 76
1991 67
1992 98
1993 68
1994 88
1995 83
1996 67
1997 90
1998 101
1999 133
2000 120
2001 109
2002 99
2003 123
2004 118
2005 140
2006 155
2007 154
2008 175
2009 198
2010 229
2011 213
2012 218
2013 238
2014 213
2015 227
2016 235
2017 230
2018 230
2019 232
2020 231
2021 263
2022 254
2023 204
2024 91

Text availability

Article attribute

Article type

Publication date

Search Results

5,360 results

Results by year

Filters applied: . Clear all
Page 1
Mesalamine in the treatment and maintenance of remission of ulcerative colitis.
Ham M, Moss AC. Ham M, et al. Expert Rev Clin Pharmacol. 2012 Mar;5(2):113-23. doi: 10.1586/ecp.12.2. Expert Rev Clin Pharmacol. 2012. PMID: 22390554 Free PMC article. Review.
Ulcerative colitis (UC) is a chronic disease of the GI tract that is characterized by mucosal inflammation in the colon. Mesalamine (mesalazine) is a 5-aminosalicylic acid compound that is the first-line treatment for patients with mild-to-moderate UC. There are mul …
Ulcerative colitis (UC) is a chronic disease of the GI tract that is characterized by mucosal inflammation in the colon. Mesalamine ( …
Mesalamine with MMX technology for the treatment of ulcerative colitis.
Schreiber S, Kamm MA, Lichtenstein GR. Schreiber S, et al. Expert Rev Gastroenterol Hepatol. 2008 Jun;2(3):299-314. doi: 10.1586/17474124.2.3.299. Expert Rev Gastroenterol Hepatol. 2008. PMID: 19072380 Review.
Mesalamine with MMX Multi Matrix System technology (hereafter referred to as MMX mesalamine) is an oral, high-strength (1.2 g/tablet), once-daily formulation of 5-aminosalicylic acid used for the treatment of ulcerative colitis. ...Once remission was achieved, MMX …
Mesalamine with MMX Multi Matrix System technology (hereafter referred to as MMX mesalamine) is an oral, high-strength (1.2 g/ …
Mesalamine delivery systems: do they really make much difference?
Qureshi AI, Cohen RD. Qureshi AI, et al. Adv Drug Deliv Rev. 2005 Jan 6;57(2):281-302. doi: 10.1016/j.addr.2004.08.008. Adv Drug Deliv Rev. 2005. PMID: 15555743 Review.
Other mesalamine delivery systems use pH-dependant- or moisture-release to liberate the active mesalamine in both the large and small bowel. Direct application of mesalamine via enema or suppository is also effective in patients with distal colitis. ...
Other mesalamine delivery systems use pH-dependant- or moisture-release to liberate the active mesalamine in both the large an …
MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis.
Hu MY, Peppercorn MA. Hu MY, et al. Expert Opin Pharmacother. 2008 Apr;9(6):1049-58. doi: 10.1517/14656566.9.6.1049. Expert Opin Pharmacother. 2008. PMID: 18377346 Review.
A high-dose, once-daily formulation of 5-ASA known as MMX mesalamine has recently been approved for the treatment of UC. OBJECTIVE: To summarize current data on MMX mesalamine and to discuss its impact on management of UC. ...CONCLUSION: MMX mesalamine is the …
A high-dose, once-daily formulation of 5-ASA known as MMX mesalamine has recently been approved for the treatment of UC. OBJECTIVE: T …
Modern use of 5-aminosalicylic acid compounds for ulcerative colitis.
Le Berre C, Roda G, Nedeljkovic Protic M, Danese S, Peyrin-Biroulet L. Le Berre C, et al. Expert Opin Biol Ther. 2020 Apr;20(4):363-378. doi: 10.1080/14712598.2019.1666101. Epub 2019 Sep 18. Expert Opin Biol Ther. 2020. PMID: 31498003 Review.
Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine.
Oliveira L, Cohen RD. Oliveira L, et al. Drug Des Devel Ther. 2011 Feb 27;5:111-6. doi: 10.2147/DDDT.S5392. Drug Des Devel Ther. 2011. PMID: 21448448 Free PMC article. Review.
The aminosalicylates (5-ASA; also referred to as mesalamine-based agents) are considered as first-line in the maintenance of remission of mild to moderate ulcerative colitis (UC). Traditionally these agents have required a large pill burden and multiple daily dosing regime …
The aminosalicylates (5-ASA; also referred to as mesalamine-based agents) are considered as first-line in the maintenance of remissio …
Topical therapy.
Gross V. Gross V. Dig Dis. 2012;30 Suppl 3:92-9. doi: 10.1159/000342730. Epub 2013 Jan 3. Dig Dis. 2012. PMID: 23295698 Review.
Topical therapy with mesalazine and/or corticosteroids is the standard treatment for patients with distal ulcerative colitis. Rectal mesalazine is more effective than rectal systemically active corticosteroids or topically active corticosteroids like budesonide. ...
Topical therapy with mesalazine and/or corticosteroids is the standard treatment for patients with distal ulcerative colitis. Rectal …
Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease.
Moja L, Danese S, Fiorino G, Del Giovane C, Bonovas S. Moja L, et al. Aliment Pharmacol Ther. 2015 Jun;41(11):1055-65. doi: 10.1111/apt.13190. Epub 2015 Apr 13. Aliment Pharmacol Ther. 2015. PMID: 25864873 Free article. Review.
BACKGROUND: Budesonide and mesalazine (mesalamine) are commonly used in the medical management of patients with mild to moderate Crohn's disease. ...The occurrence of withdrawals due to adverse events was not shown different between budesonide, mesalazine and …
BACKGROUND: Budesonide and mesalazine (mesalamine) are commonly used in the medical management of patients with mild to modera …
Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis.
Barberio B, Segal JP, Quraishi MN, Black CJ, Savarino EV, Ford AC. Barberio B, et al. J Crohns Colitis. 2021 Jul 5;15(7):1184-1196. doi: 10.1093/ecco-jcc/jjab010. J Crohns Colitis. 2021. PMID: 33433562 Free article.
High-dose [3.3 g/day] oral mesalazine ranked third in most analyses, with the most trials and most patients. For relapse of disease activity, combined therapy and high-dose oral mesalazine ranked first and second, with topical mesalazine third. 5-ASAs were sa …
High-dose [3.3 g/day] oral mesalazine ranked third in most analyses, with the most trials and most patients. For relapse of disease a …
[Mesalazine-induced myocarditis].
Koh Y, Nagaya T, Saegusa H, Ikeuchi H, Kodama R, Ushimaru H. Koh Y, et al. Nihon Shokakibyo Gakkai Zasshi. 2020;117(12):1093-1099. doi: 10.11405/nisshoshi.117.1093. Nihon Shokakibyo Gakkai Zasshi. 2020. PMID: 33298675 Japanese.
He was suspected of having ulcerative colitis, and administration of 2400mg/day of oral mesalazine was initiated. After 10 days of treatment, he experienced fever and chest pain. ...Prompt cessation of mesalazine quickly improved his heart function and test results. …
He was suspected of having ulcerative colitis, and administration of 2400mg/day of oral mesalazine was initiated. After 10 days of tr …
5,360 results